1205-62-5

Usage

Uses

Used in Dye-Sensitized Solar Cell Devices:
(4-Nitro-benzyl)-phosphonic acid is used as a self-assembling molecule for tuning the electronic properties of electrodes in Dye-Sensitized Solar Cell Devices. Its self-assembly capability allows for the creation of well-ordered structures on oxide surfaces, which can enhance the performance of the solar cells by improving charge transport and light absorption.
Used in Surface Modification:
(4-Nitro-benzyl)-phosphonic acid is used as a surface modifier for various oxide materials. Its ability to self-assemble on oxide surfaces makes it a valuable tool for modifying the surface properties of materials, which can be beneficial in a range of applications, from improving the performance of electronic devices to enhancing the biocompatibility of medical implants.
Used in Chemical Synthesis:
(4-Nitro-benzyl)-phosphonic acid can be used as a building block or intermediate in the synthesis of more complex organic compounds, particularly those with phosphonic acid or nitro-benzyl functional groups. Its unique structure and reactivity make it a versatile component in the development of new molecules with specific properties and applications.

Upstream product

• 6881-57-8 benzylphosphonic acid 
• 3900-19-4 (4-nitro-benzyl)-phosphonic acid dibutyl ester 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 100-39-0 benzyl bromide 
• 1080-32-6 O,O-diethyl benzylphosphonate 
• 122-52-1 triethyl phosphite 
• 2609-49-6 diethyl p-nitrobenzylphosphonate 
• 100-52-7 benzaldehyde 
• 3762-27-4 dibutyl benzylphosphonate 

Downstream Products

• 5424-27-1 (p-aminobenzyl)phosphonic acid 
• 99-99-0 1-methyl-4-nitrobenzene 
• 57919-10-5 phosphoric acid monoethyl ester; bis-deprotonated form 
• 1623-14-9 ethyl phosphate 
• 736-30-1 1,2-bis(4-nitrophenyl)ethane 
• 620162-40-5 benzyl phosphate 
• 14561-15-0 2.4-Dinitrobenzyl-phosphonsaeure 
• 160007-27-2 (4-nitrobenzyl)phosphonic dichloride 
• 162210-31-3 2-(4-aminobenzyl)-1,3,2-dioxaphosphorinan-2-oxide 
• 162210-26-6 2-(4-nitrobenzyl)-1,3,2-dioxaphosphorinan-2-oxide 
• 162210-34-6 2-(4-aminobenzyl)-1,3,2-dioxaphosphepan-2-oxide 
• 162210-29-9 2-(4-nitrobenzyl)-1,3,2-dioxaphosphepan-2-oxide 
• 132573-75-2 4-nitrobenzylphosphonothioic dichloride 
• 229006-84-2 2-(4-aminobenzyl)-1,3-dimethyl-1,3,2-diazaphosphorinane-2-oxide 

Relevant academic research and scientific papers

Serendipitous assemblies of two large phosphonate cages: A Co15 distorted molecular cube and a Co12 butterfly type core structure

This report describes the synthesis, characterization, and magnetic properties of two novel phosphonate-based CoII cages. Structural investigation reveals some interesting geometrical features in the molecular core that may provide new models in single molecular magnetic materials.

Synthesis, crystal structure and computational studies of 4-nitrobenzylphosphonic acid

4-Nitrobenzylphosphonic acid (1a) has been synthesized and structurally characterized by vibrational spectroscopy (IR and Raman) and single-crystal X-ray diffraction. Additionally, Hirshfeld surface analysis and computational methods have been used to com

Crystal structures of the apo form and a complex of human LMW-PTP with a phosphonic acid provide new evidence of a secondary site potentially related to the anchorage of natural substrates

Low molecular weight protein tyrosine phosphatases (LMW-PTP, EC 3.1.3.48) are a family of single-domain enzymes with molecular weight up to 18 kDa, expressed in different tissues and considered attractive pharmacological targets for cancer chemotherapy. Despite this, few LMW-PTP inhibitors have been described to date, and the structural information on LMW-PTP druggable binding sites is scarce. In this study, a small series of phosphonic acids were designed based on a new crystallographic structure of LMW-PTP complexed with benzylsulfonic acid, determined at 2.1 ?. In silico docking was used as a tool to interpret the structural and enzyme kinetics data, as well as to design new analogs. From the synthesized series, two compounds were found to act as competitive inhibitors, with inhibition constants of 0.124 and 0.047 mM. We also report the 2.4 ? structure of another complex in which LMW-PTP is bound to benzylphosphonic acid, and a structure of apo LMW-PTP determined at 2.3 ? resolution. Although no appreciable conformation changes were observed, in the latter structures, amino acid residues from an expression tag were found bound to a hydrophobic region at the protein surface. This regions is neighbored by positively charged residues, adjacent to the active site pocket, suggesting that this region might be not a mere artefact of crystal contacts but an indication of a possible anchoring region for the natural substrate - which is a phosphorylated protein.

Designing anti-inflammatory drugs from parasitic worms: A synthetic small molecule analogue of the acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis

In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects on relevant macrophage cytokine responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in an in vivo model of inflammation, collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development.

AMINO PYRIMIDINE ANTICANCER COMPOUNDS

Compounds of Formula (1), as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.

Nucleophilic Substitution in Benzylic Thiophosphinyl and Thiophosphonyl Chlorides: the Contribution of Elimination-Addition Pathways with Methylenethiooxophosphorane (Thiophosphene) Intermediates

For the reactions of ArCH2P(S)(Ph)Cl and ArCH2P(S)(NMe2)Cl with Et2NH, changing ArCH2 from benzyl to 4-nitrobenzyl increases the rates of substitution by factors of 80 and >103, respectively, and reduces markedly the ability to discriminate bet